Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy Neoadjuvante Chemotherapie mit Cabazitaxel vor der radikalen Prostatektomie

Next Previous
Trial Profile

Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy Neoadjuvante Chemotherapie mit Cabazitaxel vor der radikalen Prostatektomie

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms CLUBNET-CABAZ
  • Sponsors Sanofi

Most Recent Events

  • 12 Sep 2016 Status changed from suspended to discontinued as the investigator left the site
  • 15 Sep 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
  • 12 Sep 2013 Planned end date changed from 12 Jun 2015 to 1 Aug 2018, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top